(Q42910898)

English

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers

scientific article published on June 1, 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

H. Shao

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20831536

10 July 2024

X. M. Ren

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20831536

10 July 2024

N. F. Liu

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20831536

10 July 2024

G. M. Chen

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20831536

10 July 2024

W. L. Li

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20831536

10 July 2024

Z. H. Zhai

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20831536

10 July 2024

D. W. Wang

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20831536

10 July 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20831536

10 July 2024

publication date

1 June 2010

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

full work available at URL

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2710.2009.01134.x

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20831536

10 July 2024

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2710.2009.01134.x

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2710.2009.01134.x/fullpdf

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

Journal of Clinical Pharmacy and Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

35

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

351-360

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

CYP2C19 polymorphism and proton pump inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01134.X

21 January 2018

Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes

1

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

Allele and genotype frequencies of CYP2C9 in a Korean population

2

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers

3

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans

4

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes.

5

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers

6

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms

7

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects

8

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future

9

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.

10

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

Drug metabolism and variability among patients in drug response

11

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians

12

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations

13

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

CYP2C19 genotype and phenotype determined by omeprazole in a Korean population

14

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole

15

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism

16

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

Cytochrome P450 2C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitis

17

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus

19

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination

20

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects

21

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents

22

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

An improved gel-based DNA microarray method for detecting single nucleotide mismatch

23

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations

25

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes

26

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide

27

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate

28

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide

29

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes

30

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

In vivo modulation of CYP enzymes by quinidine and rifampin

31

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

Gliclazide modified release: from once-daily administration to 24-hour blood glucose control.

32

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

Gliclazide directly inhibits arginine-induced glucagon release

33

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

35

1 reference

10.1111/J.1365-2710.2009.01134.X

https://api.crossref.org/works/10.1111/J.1365-2710.2009.01134.X

10 July 2024

Identifiers

10.1111/J.1365-2710.2009.01134.X

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42910898&oldid=2200429577"